Equillium, Inc. - Common Stock, par value $0.0001 per share (EQ)
CUSIP: 29446K106
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 65,456,657
- Total 13F shares
- 8,709,051
- Share change
- +148,849
- Total reported value
- $2,740,934
- Price per share
- $0.32
- Number of holders
- 27
- Value change
- +$38,410
- Number of buys
- 12
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 29446K106?
CUSIP 29446K106 identifies EQ - Equillium, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29446K106:
Top shareholders of EQ - Equillium, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Decheng Capital LLC |
13F
|
Company |
6.8%
|
4,447,308
|
$1,744,679 | — | 31 Mar 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
|
Company |
2.8%
|
1,824,977
|
$711,741 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.3%
|
841,948
|
$330,044 | — | 31 Mar 2025 | |
| Cota Capital Management, LLC |
13F
|
Company |
0.86%
|
562,278
|
$220,582 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.41%
|
269,500
|
$105,725 | — | 31 Mar 2025 | |
| Jason A. Keyes |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
126,633
|
$82,311 | — | 14 Feb 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.31%
|
205,367
|
$80,582 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.17%
|
108,691
|
$40,000 | — | 31 Mar 2025 | |
| Callan Capital, LLC |
13F
|
Company |
0.15%
|
99,688
|
$39,108 | — | 31 Mar 2025 | |
| Joel Rothman |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
233,150
mixed-class rows
|
$33,727 | — | 02 Jan 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.09%
|
59,720
|
$23,428 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.09%
|
55,649
|
$21,831 | — | 31 Mar 2025 | |
| DCF Advisers, LLC |
13F
|
Company |
0.06%
|
39,492
|
$15,493 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.06%
|
36,967
|
$14,502 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.05%
|
35,019
|
$13,738 | — | 31 Mar 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.04%
|
25,000
|
$10,000 | — | 31 Mar 2025 | |
| TRITONPOINT WEALTH, LLC |
13F
|
Company |
0.02%
|
13,500
|
$5,296 | — | 31 Mar 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.02%
|
13,954
|
$5,000 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
10,238
|
$4,016 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
6,819
|
$2,675 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
1,721
|
$675 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
1,000
|
$392 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
865
|
$339 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
151
|
$59 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
38
|
$15 | — | 31 Mar 2025 | |
| Bala S. Manian |
3/4/5
|
Director |
—
mixed-class rows
|
40,000
mixed-class rows
|
— | — | 21 May 2025 | |
| Barbara Troupin |
3/4/5
|
Director |
—
mixed-class rows
|
40,000
mixed-class rows
|
— | — | 21 May 2025 | |
| Charles Douglas McDermott |
3/4/5
|
Director |
—
mixed-class rows
|
40,000
mixed-class rows
|
— | — | 21 May 2025 | |
| Mark Pruzanski |
3/4/5
|
Director |
—
mixed-class rows
|
40,000
mixed-class rows
|
— | — | 21 May 2025 | |
| Martha J. Demski |
3/4/5
|
Director |
—
mixed-class rows
|
40,000
mixed-class rows
|
— | — | 21 May 2025 | |
| Peter Colabuono |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 21 May 2025 | |
| Ph.D. Yu Xu |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 22 May 2024 |
Institutional Holders of Equillium, Inc. - Common Stock, par value $0.0001 per share (EQ) as of Q2 2025
As of 30 Jun 2025,
Equillium, Inc. - Common Stock, par value $0.0001 per share (EQ) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,709,051 shares.
The largest 10 holders included
Decheng Capital LLC, TAKEDA PHARMACEUTICAL CO LTD, VANGUARD GROUP INC, Cota Capital Management, LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, UBS Group AG, STATE STREET CORP, and AlphaCore Capital LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
23
Q2 2025 holders
27
Holder diff
4
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.